SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor Technologies (OPEN) is currently trending due to recent announcements aimed at significantly lowering mortgage rates and boosting the broader housing market. This news has ignited strong community optimism, with many anticipating a substantial increase in transaction volume and a potential short squeeze for the real estate technology stock. Despite ongoing discussions about company fundamentals and potential warrant dilution, a prevailing bullish sentiment suggests a significant upside for OPEN within the revitalized housing sector.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is currently facing heightened market uncertainty, as investors closely monitor the anticipated Supreme Court ruling on tariffs and upcoming economic data, including the jobs report. Community sentiment is sharply divided, with some anticipating new highs while others express concern about Nasdaq losing momentum and potential market manipulation amidst broader geopolitical and political policy shifts.

Polygon

Polygon is actively trending amid significant discussion surrounding its utility and institutional adoption, with reports of BlackRock investments and J.P. Morgan leveraging its DeFi capabilities, alongside integrations with platforms like Instagram. The community is eagerly debating a potential return to the familiar MATIC ticker, balancing Polygon's ongoing technical advancements as a leading Ethereum Layer 2 solution with strong brand recognition. This confluence of major partnerships and an internal brand identity discussion is fueling widespread conversation.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending amid intensifying industry focus on photonics for AI infrastructure, notably following NVIDIA's CES presentation highlighting optical networking in its new Vera Rubin platform. The community is actively discussing POET's unique optical interposer technology and strategic partnerships, seeing them as crucial for enabling high-speed, energy-efficient data transfer needed for next-generation AI data centers. This strong positioning, coupled with recent analyst optimism and strategic acquisitions in the sector, fuels speculation about imminent news or major orders despite current management silence as commercialization is expected to ramp significantly through 2026.

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) PLC

SMX is trending following its announcement of strengthening its balance sheet by converting convertible notes into equity, aiming to eliminate corporate-level indebtedness and reduce future dilution concerns. This development has ignited fervent discussions among investors, with many anticipating a massive short squeeze due to high cost-to-borrow and limited share availability, drawing comparisons to past volatile movers. Conversely, a skeptical segment highlights the company's history of volatility and lack of revenue, fostering a highly debated and speculative environment around the stock.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Holdings Inc

Ondas Holdings is trending due to reports that its subsidiary, Airobotics, has been selected as the prime contractor for Israel's Eastern Border Security Barrier project, a significant development in autonomous defense systems. The community is highly bullish, comparing ONDS to Palantir and anticipating substantial growth driven by increasing defense budgets and the company's strategic positioning in the rapidly evolving drone and AI sector.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

ARDX is trending as investors digest the potential impact of Fosun Pharma's Wan Ti Le being included on China's National Reimbursement Drug List and analysts anticipate target price raises due to strong IBSRELA sales. The community is weighing potential revenue from China and speculating on milestone payments, while also discussing concerns about patent infringement and generic competition. Some investors express frustration with the stock's price movement despite positive developments, awaiting a CMS resolution.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU is trending with robust community support, driven by active development of real-world products like Kendu Spice and Energy drinks. The project garners strong bullish sentiment for its continuous building efforts, significant IRL presence, and long-term vision to establish a prominent brand within the crypto ecosystem.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines (LUNR) is generating significant community buzz, primarily driven by strong anticipation for a multi-billion dollar NASA Lunar Terrain Vehicle (LTV) contract award. Investors are also noting a recently identified federal contract with NASA and the strategic Lanternis acquisition, positioning LUNR as a key player in the expanding aerospace and defense sector. This widespread bullish sentiment is fueled by expectations of a substantial price surge upon the LTV announcement, with many observing increased short activity.

Pippin is an SVG unicorn drawn using the latest LLM benchmarks on ChatGPT 4o. It is an autonomous AI agent on X. Pippin was created by Yohei Nakajima, a recognised innovator and thought leader in the Al VC space (followed by Jeff Bezos and Marc Andreessen). He is known for his build-in-public approach and has been at the forefront of the ‘AI for VC’ movement, launching over 100+ AI-driven prototypes, automation agents &amp; open-source projects.  His most notable build is BabyAGI (March 2023), the first popular open-source autonomous agent with task-planning capability. The project went viral on Twitter amassing millions of impressions and resulting in tens of thousands of GitHub stars, dozens of Arxiv citations, coverage across major online media publications globally, and many speaker engagements including the inaugural TED AI in San Francisco.

pippin

PIPPIN CRYPTO is trending due to significant price surges, reportedly fueled by short squeezes and recent exchange listings for this Solana-based, AI-driven project. Community sentiment is sharply divided, with many celebrating its strong performance and resilience, while a vocal segment warns of it being a potential scam, citing concerns over concentrated whale holdings and manipulated volume.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>JNJ agreed to drug discounts and tariff exemptions under a White House deal.</li><li>The agreement builds on its existing $55 billion U.S. manufacturing and R&amp;D plan.</li><li>New facilities add to projects already underway in North Carolina and Pennsylvania.</li></ul><p>Johnson &amp; Johnson (JNJ) said on Thursday it has reached a voluntary agreement with the U.S. government to expand access to medicines, lower drug costs for American patients, and secure exemptions from U.S. tariffs on its pharmaceutical products, while advancing its domestic manufacturing plans.</p><h2 class="st-heading-2"><strong>Drug Pricing And Tariff Exemptions</strong></h2><p>As part of the deal, JNJ will allow Americans to buy medicines at significantly discounted rates through TrumpRx.gov, a government-backed direct-to-patient platform. The company will also provide U.S. Medicaid programs access to medicines at prices comparable to those in other developed countries.</p><p>The deal grants JNJ’s pharmaceutical products exemptions from U.S. tariffs and aligns with the administration’s “most-favored-nation” pricing framework.</p><p>“Today’s agreement shows that when the public and private sectors work together towards shared goals, we can deliver real results for patients and the U.S. economy,” CEO Joaquin Duato said in a statement.&nbsp;</p><h2 class="st-heading-2"><strong>US Manufacturing Commitments</strong></h2><p>JNJ said the agreement builds on its previously announced $55 billion U.S. investment plan through early 2029, which focuses on expanding domestic manufacturing, research and development, and technology.&nbsp;</p><p>As part of the plan, the company announced two additional U.S. manufacturing facilities, including a cell therapy site in Pennsylvania and a drug product manufacturing facility in North Carolina. Construction is already underway at the company’s $2 billion biologics facility in Wilson, North Carolina, a project expected to support around 5,000 manufacturing and construction jobs.&nbsp;</p><p>Separately, JNJ has committed $2 billion over the next 10 years to a biopharmaceutical site in Holly Springs, North Carolina, which is expected to create about 120 jobs. The company said it expects to announce further U.S. investments later this year.</p><h2 class="st-heading-2"><strong>White House Drug Deals Expand</strong></h2><p>The announcement follows&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-strikes-new-drug-price-deals-with-roche-novartis-merck-and-other-pharma-giants/cLe0duBREtP">similar agreements struck last month</a> between the White House and other major drugmakers, including Amgen, Bristol Myers Squibb, Pfizer, Gilead Sciences, GSK, Merck, Novartis, Roche and Sanofi.</p><p>The deals require steep discounts through TrumpRx, most-favored-nation pricing for Medicaid, expanded U.S. manufacturing, and restrictions on stockpiling drugs to avoid tariffs.</p><h2 class="st-heading-2"><strong>How Did Stocktwits Users React?</strong></h2><p>On Stocktwits, retail sentiment was ‘bearish’ amid ‘high’ message volume.</p><figure class="image"><img src="https://news.stocktwits-cdn.com/jnj_ss_png_1d85f7828a.webp" alt="jnj ss.png" width="967" height="142"><figcaption>JNJ sentiment and message volume as of January 8| Source: Stocktwits</figcaption></figure><p><a href="https://stocktwits.com/symbol/JNJ">JNJ’s stock</a> has risen 49% over the past 12 months.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, a Johnson & Johnson logo seen displayed on a monitor. (Photo Illustration by Valera Golovniov/SOPA Images/LightRocket via Getty Images)

J&J Cuts Deal With Trump’s White House To Slash Drug Prices And Dodge Tariffs 

The company will also provide U.S. Medicaid programs access to medicines at prices comparable to those in other developed countries.

Equity

GILD February 27th Options Begin Trading

Investors in Gilead Sciences Inc (Symbol: GILD) saw new options begin trading today, for the February 27th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the GILD...

Here's Why Gilead Sciences (GILD) is a Strong Momentum Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Perhaps We Should Actually Be Focusing On Fixing America

Perhaps We Should Actually Be Focusing On Fixing America Authored by Michael Snyder via TheMostImportantNews.com, After years of heading in the wrong direction, nobody can deny that the United States...

Robeco Institutional Asset Management B.V. Purchases 59,295 Shares of Gilead Sciences, Inc. $GILD

Robeco Institutional Asset Management B.V. boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 1.6% during the third quarter, according to the company in its most...

Gilead Sciences (GILD) Stock Declines While Market Improves: Some Information for Investors

Gilead Sciences (GILD) concluded the recent trading session at $118.3, signifying a -2.71% move from its prior day's close.

KYMR Skyrockets 82.4% in a Year: More Upside Potential in 2026?

KYMR rallied 82% in a year as KT-621 delivered strong phase Ib BroADen data and earned FDA Fast Track for atopic dermatitis.

11,480 Shares in Gilead Sciences, Inc. $GILD Bought by TriaGen Wealth Management LLC

TriaGen Wealth Management LLC bought a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the third quarter, according to its most recent 13F filing with the Securities...

Railway Pension Investments Ltd Purchases 42,200 Shares of Gilead Sciences, Inc. $GILD

Railway Pension Investments Ltd increased its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 3.1% in the 3rd quarter, according to its most recent disclosure with the Securities and...

CWA Asset Management Group LLC Has $6.08 Million Position in Gilead Sciences, Inc. $GILD

CWA Asset Management Group LLC reduced its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 16.6% during the 3rd quarter, according to the company in its most recent 13F filing with the...

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Gilead Sciences, Inc.

Yes — Rates Move Meaningfully Lower

Short-Term Dip, No Lasting Impact

No — Mostly Political Noise

Other – Comment Below

President Trump says he’s directing $200 billion into mortgage bond purchases to bring down rates and improve housing affordability. With questions around execution, authority, and real market impact, do you think this move will actually lower mortgage rates in 2026?

Will Trump’s Mortgage Bond Plan Actually Lower Rates in 2026?

GILD
Gilead Sciences, Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest GILD News

GILDGilead Sciences, Inc.